ProCE Banner Activity

CE / CME

A Community Practitioner’s Guide to Contemporary Management of Polycythemia Vera: Data Review and Case Challenges Illustrating Current Best Practice

Video

Watch this CME/CNE/CPE/AAPA-certified webcast from a live presentation by John Mascarenhas, MD, on community team management of polycythemia vera, including risk stratification guiding cytoreductive therapy, dose optimization considering response and tolerance, and identification of factors that inform a treatment switch.

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

Nurses: 1.00 Nursing contact hour

Physicians: maximum of 1.00 AMA PRA Category 1 Credit

Pharmacists: 1.00 contact hour (0.1 CEUs)

Released: November 06, 2023

Expiration: November 05, 2024

Share

Faculty

John Mascarenhas

John Mascarenhas, MD

Director, Adult Leukemia Program
Leader, Myeloproliferative Disorders Clinical Research Program
Division of Hematology/Oncology
Tisch Cancer Institute 
Professor of Medicine
Icahn School of Medicine at Mount Sinai
New York, New York

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from PharmaEssentia USA Corporation and Incyte Corporation.

Incyte Corporation

PharmaEssentia USA Corporation

Target Audience

This program is intended for community-based medical hematologists/oncologists, advanced practice providers, nurses, pharmacists, and other healthcare professionals involved in the treatment of patients with polycythemia vera.

Program Learning Goal

The goal of this program is to improve the knowledge, competence, and performance of learners in effort to optimize treatment for patients with Myeloproliferative neoplasms (MPN)

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Identify factors used to stratify risk and indications for initiating cytoreductive therapy in PV, including potentially disease-modifying therapies in low-risk PV

  • Recognize symptoms and patterns of first-line treatment failure in patients with MPNs, including treatment intolerance and treatment resistance

  • Institute best practices for transitioning to a clinically appropriate second-line therapy after first-line treatment failure for patients with PV

  • Integrate supportive care plans into practice that are designed to monitor symptoms and manage treatment-related toxicities from current PV treatments

  • Review data on emerging novel targets and mechanisms that have the potential to change clinical practice in PV

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

John Mascarenhas, MD

Director, Adult Leukemia Program
Leader, Myeloproliferative Disorders Clinical Research Program
Division of Hematology/Oncology
Tisch Cancer Institute 
Professor of Medicine
Icahn School of Medicine at Mount Sinai
New York, New York

John Mascarenhas, MD: consultant/advisor/speaker: AbbVie, Bristol Myers Squibb, Celgene, CTI Bio, Geron, GlaxoSmithKline, Imago, Incyte, Kartos, Kayropharm, MorphoSys, Novartis, Pfizer, PharmaEssentia, Sierra; researcher: AbbVie, Bristol Myers Squibb, Celgene, CTI Bio, Geron, Incyte, Novartis.

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1 hour. To successfully complete this activity and receive credit, learners must follow these steps during the period from November 06, 2023, through November 05, 2024:

  1. Login or Sign Up for an account by clicking at the top of this page
  2. Read the target audience, learning objectives, and faculty disclosures
  3. View and study the content in its entirety
  4. Submit answers to the post-test questions and evaluation questions online

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement
Joint AccreditationIn support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

 

Physician Continuing Medical Education

CCO designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development
The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1 contact hour.

Continuing Pharmacy Education

CCO designates this continuing education activity for 1 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education.

Universal Activity Number - JA4008176-0000-23-280-H01-P 
Type of Activity: Application

Upon successfully completing the post-test with a score of 65 or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Physician Associate Continuing Medical Education
Joint AccreditationClinical Care Options, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credit. Approval is valid until November 05, 2024. PAs should only claim credit commensurate with the extent of their participation.